Novavax appoints senior vp of business development

Russell ‘Rip’ Wilson takes the role at US biopharmaceutical firm

US biopharmaceutical firm Novavax has appointed Russell ‘Rip’ Wilson as senior vice president of business development. He takes responsibility for developing business alliances, licensing arrangements, and partnering opportunities with pharmaceutical companies and government agencies.

Wilson was most recently chief financial officer at Supernus Pharmaceuticals. He was previously senior vice president, chief financial officer and general counsel of Iomai Corporation, which was acquired in 2008 by Intercell. He was also the acting general counsel of North American Vaccine, until its acquisition by Baxter International in 2000.

You may also like

Manufacturing

Novavax sells protein manufacturing facility to Novo Nordisk for $200m

Novo Nordisk's purchase of Novavax's Czech recombinant protein manufacturing facility will involve a full transfer of assets — including its workforce and associated support buildings
Manufacturing

Ardena expands capacity for COVID vaccine production

The expansion follows the grant of conditional marketing authorisation by the European Commission for Novavax’s Nuvaxovid COVID-19 vaccine
Research & Development

US HHS awards influenza contracts worth US$215m

Novavax and VaxInnate to develop VLP and recombinant influenza vaccines, respectively
Regulatory

FDA clears Novavax RSV vaccine candidate for early stage trial

Novavax resolves question about chemistry, manufacturing and controls
Research & Development

Novavax terminates negotiations with ROVI Pharmaceuticals

US biotech Novavax has ended talks aimed at negotiating the terms of a collaboration with Spanish drugmaker ROVI Pharmaceuticals to develop Novavax\'s virus-like-particle (VLP)-based vaccines against influenza.
Manufacturing

AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn

AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance

GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors

GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
Subscribe now